Indirect evidence from clinical observations has suggested that chronic cellular hypoxia influences the radiocurability of some human malignancies (Bush et al., 1978; Henk & Smith, 1977; Urtasun et al., 1976) . Trials of strategies to overcome the oxygen effect have had no reliable technique available for confirming the presence of hypoxic cells in tumours of the patients on study. For this reason, the development of predictive assays of tumour oxygenation status is of great interest in radiotherapy. In a study of oxygen tension mapping in cervical lymph node metastases from squamous cell carcinomas of the head and neck, Gatenby et al. (1985 Gatenby et al. ( , 1988 showed that extensive areas of hypoxia, determined by oxygen electrode measurements, were significantly correlated with tumour radioresponse, and were independent of tumour bulk. Radiosensitiser adduct formation has been shown to identify hypoxic cells in vitro and in solid animal tumour models (Chapman et al., 1981; Garrecht & Chapman, 1983; Franko et al., 1982) . Clinical data from a study of 3H-misonidazole in advanced cancer patients show evidence for hypoxic regions in biopsies of subcutaneous metastases. In this study, hypoxic fractions of potential clinical significance were determined to be present in 3/3 melanomas, 8/12 small cell lung carcinomas, 1/10 soft tissue sarcomas, and 0/2 squamous cell carcinomas of the head and neck (Chapman et al., 1989a) . This technique, however, is invasive, requires careful radiation protection safeguards, is only applicable to accessible lesions and is time consuming. Therefore, rapid, non-invasive predictive assays for hypoxia are under development.
The radioiodinated azomycin nucleosides are misonidazole analogues labelled with iodine-123 which show promise for use in the detection of tumour hypoxia using conventional nuclear medicine techniques Wiebe et al., 1986) . Iodoazomycin arabinoside (Figure 1, IAZA) has been shown to undergo hypoxia-dependent binding and is cytotoxic to EMT-6 tumour cells in vitro (Mannan et al., 1991; Mercer et al., 1990) . Recently, it has been shown using autoradiography that '25I-IAZA binds to hypoxic regions of EMT-6 spheroids in a manner analogous to 3H-misonidazole (G.G. Miller, Ph.D., personal communication) . Whole body biodistribution studies using implanted EMT-6 tumours in BALB/c mice show a maximum tumour to whole blood ratio of 8.7 at 8 h post injection. These promising results have lead to the current clinical study investigating '23I-iodoazomycin arabinoside ('23I-IAZA) as a potential non-invasive marker for hypoxia. The aim of this study is to establish the toxicity of IAZA in patients, as well as its pharmacokinetics, biodistribution and tumour uptake. This work in progress forms the basis for this report.
Materials and methods

Radiopharmaceuticals
Unlabelled IAZA (1-(5'-iodo-5'-deoxy-p-D-arabinofuranosyl)-2-nitroimidazole), was prepared in the laboratories of one of us (L.I.W.) as described elsewhere (Mannan et al., 1991 Table I. Imaging protocol 231I-IAZA (mean, 223 MBq (6.0 mCi)) was given by slow intravenous infusion over 20 min. Lugol's iodine was administered orally for 3 days prior to imaging to block thyroid uptake of free radioiodine. All imaging procedures were performed using a General Electric 400 AC gamma camera system. Image acquisition and processing was by means of a Picker PCS 512 computer system. Anterior and posterior planar static images were obtained of the area of interest, thorax and abdomen typically at 1, 16, and 24 h post injection. SPECT imaging of the area/region of interest was performed between 16-24 h post infusion. It was found that insufficient total body activity was retained for successful imaging at times greater than 24 h. Consent was obtained from three patients for blood sampling for the determination of blood and plasma pharmacokinetics.
Qualitative assessment of biodistribution utilised both planar and SPECT images. Quantitative analysis of the tissue activity was assessed using region of interest analysis on these images. On the planar images, using conjugate view counting techniques (Thomas et al., 1988) , tissue activity was determined using a square or rectangular region representing central tumour activity. On the SPECT images, coronal, axial and sagittal reconstructions were performed. For purposes of activity quantification, tomographic slices were summed to incorporate the entire dimensions of the tumour. Again, tumour activity was represented by the central tumour activity within a square or rectangular region of interest; an identically sized region of interest in adjacent normal tissue was then determined.
Results
Imaging results Immediate and 1 h static images were obtained in all cases. On early images we observed significant activity in the thyroid gland, major salivary glands, paranasal sinuses, nasal, oral, and pharyngeal mucosa, liver, kidneys and urinary bladder. On later images, there was a relative increase in thyroid and salivary gland activity, and loss of hepatic and renal uptake; gastric, small, and large intestinal activity became evident, as did activity in some tumours ( Figure 2 ). This suggested hepatic and renal routes of elimination for 1231I-IAZA and/or its metabolites; also at least partial in vivo deiodination was evident, accounting for thyroid and salivary gland uptake.
Quantitative image analysis
Regions of interest were analysed sequentially to quantify changes in relative tissue activity as a function of time between the early and late images. This analysis showed focal accumulation of activity in three of ten tumours. T/N ratios were obtained by comparing a region of interest over the tumour (T) and adjacent normal tissue (N). The T/N for those tumours showing focal uptake increased with time, the maximal T/N being 3.1 at 16h for a brain metastasis from small cell lung carcinoma. The other tumours showing uptake were a malignant fibrous histiocytoma of the thigh (T/N = 1.9 at 22 h), and a primary small cell lung carcinoma (T/N = 2.3 at 18 h) (Table II) .
These data do not represent ratios of absolute quantities of bound drug. Nonetheless, T/N ratios which increase over time (comparing early and later images) can be taken as evidence for preferential metabolic binding of the tracer in tumours. We postulate that the rise in T/N shown by patients 1, 2 and 6 (+ 16%, + 16% and + 39% respectively, Table II) represent this phenomenon, and that lesser changes or decreases in T/N as exhibited by 7/10 patients probably do not represent significant binding. Figure  3) . These results are consistent with the previously reported mean plasma half-life of 3H-misonidazole of 9 h (clearance phase) (Urtasun et al., 1986; Chapman et al., 1989a 
Discussion
There is evidence indicating that sensitiser adduct formation offers a measure of intracellular oxygen concentration. It is known that the radical anion generated by the initial one electron reduction of 2-nitroimidazoles is oxidised in the presence of sufficient oxygen (Rauth, 1984; Varghese & Whitmore, 1984 (Rauth, 1984; Varghese & Whitmore, 1984) . The absolute rates of binding to hypoxic cells are related to the concentration of drug, the concentration of 02, and the duration of contact between the drug and hypoxic tissues (Franko, 1986) . To a lesser extent, sensitiser binding rates are related to the structure of the particular 2-nitroimidazole (Chapman et al., 1989c) . It is also possible that constitutive levels of nitroreductase activity in various normal tissues affect the baseline rates of binding (Cobb et al., 1990 mence even during the infusion phase, it is clear that the maximal rates of drug binding will occur in phases II and the early part of phase III, when the concentration of unbound marker in tissue is maximal. Although the marker concentration will change with time, it is at times of maximum marker concentration in which most hypoxic cell labelling will occur; we further assume that the covalently bound sensitiser adducts are stable in tissues . Hypoxic markers will also bind to normal tissue or areas of oxic tumour, albeit at a rate at least 10-fold less than in the hypoxic tumour (Chapman et al., 1989b , Cobb et al., 1990 . This differential binding would result in a maximum tumour to normal tissue ratio of approximately ten. The development of a differential between marker signal in hypoxic and aerobic tissue will occur after the concentration of unbound drug falls below that of the bound drug in hypoxic regions.
From Figure 4 (inset), it is clear that the T/N ratio will increase with time, and should approach a limit which is governed by the differential rate of binding in hypoxic vs aerobic tissue, once unbound marker has been cleared. In this schema, it is clear that the optimal window for imaging hypoxia will occur after at least three drug half-lives. As noted in Figure 4 (inset), the hypoxic marker with a shorter pharmacologic half-life (A) displays a more rapid increase in T/N ratio with time after infusion compared to marker B.
Finally, it must be remembered that the radioactive half-life of the isotope, in contrast to the pharmacokinetic half-life of the marker molecule, must be long enough to allow for successful imaging at the optimum time (i.e. > three pharmacokinetic half-lives). This is one potential limitation of 18F-fluoromisonidazole and positron emission tomographic imaging Rasey et al., 1989) , for which the isotopic half-life is 109.7 min.
With the doses of '23I-IAZA used, the optimum time for imaging seems to be 24 h post infusion. At this time, we have observed focal accumulation of activity in three of ten lesions studied; in these patients, tumour to normal tissue ratios were seen to rise over the 24 h period subsequent to the 123I-IAZA infusion. We postulate that this represents metabolic binding of the tracer in these tumours due to sensitiser adduct formation in hypoxic regions. However, the in vivo stability of the carbon/iodine linkage is of some concern, since, partial in vivo deiodination was observed from scintigraphic data. We plan to perform sequential HPLC analyses from plasma specimens to determine the extent and time course of this phenomenon. It is recognised that the patient population of this pilot study is heterogeneous in terms of histologic type and prior treatment. No correlation was seen between '231I-IAZA dose and uptake. Seven of the ten patients imaged were undergoing, or had just begun to receive cytotoxic therapy (radiotherapy in five cases and chemotherapy in two, Table  I ). It is unknown to what extent reoxygenation may have occurred in these patients after one or more fractions of radiotherapy. Nonetheless, two out of seven treated tumours showed '23I-IAZA avidity, while such avidity was seen in one out of three untreated tumours. We plan to investigate the change in '231I-IAZA avidity with time in selected patients, as this may lead to valuable inferences regarding reoxygenation.
Of the factors affecting the tumour microenvironment, it is likely that blood flow exerts a fundamental influence on oxygen and metabolic substrate supply (Vaupel et al., 1989 ). An experimental non-invasive marker for tumour perfusion is 9'9Tc-hexamethylpropyleneamine oxime (99'Tc-HMPAO) (Hammersley et al., 1987; Rowell et al., 1989) . We plan to investigate further the relationship between tumour '231-IAZA avidity and tumour perfusion by sequential imaging with the hypoxic marker and 99'Tc-HMPAO.
This pilot study will continue to accrue patients prior to radiotherapy. Patients will be followed and end points of tumour response and local control ascertained. There is no 'gold standard' technique for predicting tissue oxygenation, thus independent confirmation of these results is problematic. It may be possible to assess the oxygenation status of accessible lesions using needle oximetry as a comparison. Further clinical experience is required in order to determine whether the tumour uptake of IAZA or related compounds will independently correlate with radioresponsiveness and local control.
